Skip to main content
    M

    Maravai Lifesciences Holdings Inc (MRVI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.40
    -0.14 (-1.86%)

    Market Cap: $1.96B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Maravai Lifesciences Holdings Inc (MRVI) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Maravai Lifesciences Holdings are Vir Biotechnology (VIR), Sellas Life Sciences Group (SLS) and Pharvaris BV (PHVS). By market cap, Maravai Lifesciences Holdings ranks 7th of the 13 companies on this page; Vericel Corp Ord (VCEL) is the largest at $2.91B. The median P/E of the 4 companies with a P/E is 17.8x.

    Peer Comparison

    MRVI's ROIC of -28.3% is above the peer median of -29.7%, and its revenue growth of 10.1% is above the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Maravai Lifesciences Holdings (MRVI)$1.96BN/A5.2x-30.8%-28.3%10.1%0.00%
    Vir Biotechnology Inc (VIR)$1.71BN/A5.4x-61.0%N/A19582.0%0.00%
    Sellas Life Sciences Group Inc (SLS)$1.60BN/AN/A0.0%N/A-82.5%0.00%
    Pharvaris BV (PHVS)$2.36BN/AN/A0.0%N/A0.0%0.00%
    Vera Therapeutics Inc (VERA)$2.03BN/A189.3x0.0%-83.0%0.0%0.00%
    Novavax Inc (NVAX)$1.41BN/A3.2x-18.6%-66.6%-3.0%0.00%
    Harmony Biosciences Holdings (HRMY)$1.98B9.6x1.9x18.0%13.7%12.3%0.00%
    Biohaven Ltd. (BHVN)$2.09BN/AN/A0.0%-315.9%0.0%0.00%
    Forte Biosciences Inc (FBRX)$1.63BN/AN/A0.0%N/A0.0%0.00%
    Innoviva Inc (INVA)$1.35B5.3x3.0x44.1%10.8%-1.6%0.00%
    Vericel Corp Ord (VCEL)$2.91B89.8x9.1x10.3%N/A26.5%0.00%
    Beam Therapeutics Inc (BEAM)$2.36BN/A15.0x-73.9%-29.7%-96.8%0.00%
    Fortrea Holdings Inc. (FTRE)$1.95B26.0x0.7x-2.6%1.8%-1.4%0.00%
    Peer median$1.97B17.8x4.3x0.0%-29.7%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Maravai Lifesciences Holdings, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Vir Biotechnology Inc (VIR)
    Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
    VIR competitors
    Sellas Life Sciences Group Inc (SLS)
    SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications...
    SLS competitors
    Pharvaris BV (PHVS)
    Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies.
    PHVS competitors
    Vera Therapeutics Inc (VERA)
    Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases...
    VERA competitors
    Novavax Inc (NVAX)
    Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases...
    NVAX competitors
    Harmony Biosciences Holdings (HRMY)
    Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders.
    HRMY competitors
    Biohaven Ltd. (BHVN)
    Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops candidate products targeting neurological diseases and rare disorders...
    BHVN competitors
    Forte Biosciences Inc (FBRX)
    Forte Biosciences Inc. is a clinical-stage biopharmaceutical company in the United States. The company is headquartered in Torrance, California.
    Innoviva Inc (INVA)
    Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
    INVA competitors
    Vericel Corp Ord (VCEL)
    Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures...
    VCEL competitors
    Beam Therapeutics Inc (BEAM)
    Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States.
    BEAM competitors
    Fortrea Holdings Inc. (FTRE)
    Fortrea Holdings Inc. provides clinical development and patient access solutions to the life sciences industry.
    FTRE competitors

    Frequently Asked Questions About MRVI

    Who are Maravai Lifesciences Holdings' main competitors?

    The companies most similar to Maravai Lifesciences Holdings include Vir Biotechnology (VIR), Sellas Life Sciences Group (SLS), Pharvaris BV (PHVS), Vera Therapeutics (VERA) and Novavax (NVAX), listed from the closest match.

    Who is Maravai Lifesciences Holdings' biggest competitor?

    Vericel Corp Ord (VCEL) is the largest of the similar companies at $2.91B; Vir Biotechnology (VIR) is the closest match by business profile, size, sector and industry.

    How does MRVI stock compare with its competitors?

    MRVI's P/S is 5.2x against a peer median of 4.3x; its net margin is -30.8% against a peer median of 0.0%.

    Which of Maravai Lifesciences Holdings' competitors pays a higher dividend?

    Maravai Lifesciences Holdings pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Maravai Lifesciences Holdings bigger than its competitors?

    No. Maravai Lifesciences Holdings is 7th by market cap among the 13 companies on this page; the largest is Vericel Corp Ord (VCEL) at $2.91B.